| 4.32 -0.02 (-0.46%) | 06-20 13:10 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.66 | 1-year : | 6.61 |
| Resists | First : | 4.84 | Second : | 5.66 |
| Pivot price | 4.56  |
|||
| Supports | First : | 4.14 | Second : | 3.71 |
| MAs | MA(5) : | 4.36 |
MA(20) : | 4.51  |
| MA(100) : | 3.92 |
MA(250) : | 2.62 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 13.1 |
D(3) : | 20.1 |
| RSI | RSI(14): 49.4 |
|||
| 52-week | High : | 5.86 | Low : | 1 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ATHE ] has closed above bottom band by 17.0%. Bollinger Bands are 47% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.46 - 4.5 | 4.5 - 4.52 |
| Low: | 4.24 - 4.27 | 4.27 - 4.3 |
| Close: | 4.3 - 4.35 | 4.35 - 4.39 |
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Thu, 15 May 2025
Is Alterity Therapeutics Limited (ATHE) the Best Australian Stock to Buy According to Analysts? - Insider Monkey
Mon, 12 May 2025
Alterity Therapeutics highlighted at MSA Congress - Investing.com
Mon, 12 May 2025
Alterity Therapeutics Prominently Featured at the International MSA Congress - Yahoo Finance
Wed, 07 May 2025
Alterity Therapeutics reports Phase 2 data at MSA Congress - Investing.com
Mon, 05 May 2025
Breakthrough: FDA Fast-Tracks Novel MSA Drug ATH434 - First Potential Treatment for Fatal Brain Disease - Stock Titan
Sun, 04 May 2025
Alterity Therapeutics Receives US FDA Fast Track Designation; Shares Up 11% - MarketScreener
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 15 (M) |
| Shares Float | 4,310 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 1.6 (%) |
| Shares Short | 124 (K) |
| Shares Short P.Month | 57 (K) |
| EPS | -2.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -469.7 % |
| Return on Assets (ttm) | -78.4 % |
| Return on Equity (ttm) | -155.8 % |
| Qtrly Rev. Growth | -15.5 % |
| Gross Profit (p.s.) | 0.23 |
| Sales Per Share | 0.25 |
| EBITDA (p.s.) | -1.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -16 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -2.08 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 17.29 |
| Price to Cash Flow | -3.91 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|